ArQule, Inc. to Present at BMO Capital Markets Focus on Healthcare Conference on December 4, 2007.Live web cast scheduled for 10:00 a.m. eastern time WOBURN, Mass. -- ArQule, Inc. (Nasdaq: ARQL) today announced that it will present at the BMO BMO Bank of Montreal (Canada) BMO Before Market Open BMO Biometrics Management Office BMO Ballistic Missile Office BMO British Mathematical Olympiad BMO Balkan Mathematical Olympiad BMO Business Management Office Capital Markets Focus on Healthcare Conference on Tuesday, December 4, 2007 at 10:00 a.m. eastern time. ArQule's presentation will be web cast live and can be accessed through the investor relations Investor relations The process by which the corporation communicates with its investors. section of the Company's website, www.arqule.com. The conference will be held at the Millennium Broadway Hotel, 145 West 44th Street, New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . About ArQule ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy([R]) (ACT). The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis angiogenesis /an·gio·gen·e·sis/ (-jen´e-sis) vasculogenesis; development of blood vessels either in the embryo or in the form of neovascularization or revascularization. an·gi·o·gen·e·sis n. and metastasis metastasis /me·tas·ta·sis/ (me-tas´tah-sis) pl. metas´tases 1. transfer of disease from one organ or part of the body to another not directly connected with it, due either to transfer of pathogenic microorganisms or to . The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. damage response/checkpoint pathways. The Company's lead ACT program, based on the E2F-1 pathway, is partnered with Hoffman-La Roche. For more information, please visit www.arqule.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion